南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停

层级ZIF-8@Au簇纳米载体用于原位CAR-M编程及前列腺癌免疫治疗

Hierarchical Zeolitic Imidazolate Framework-8@Au Cluster Nanocarriers for In Situ Chimeric Antigen Receptor Macrophage Programming and Immunotherapy in Prostate Cancer

Zichen Liang, Rui Wang, Yiyang Wang, Qing Wang, Yihan Chen, Zehui Zhang, Mengyuan He, Jiajie Yang, Luchen Sun, Qing Zhang, Hongqian Guo, Pingping Shen, Nanfei Yang

Journal:ACS Nano

IF:16

DOI:10.1021/acsnano.5c11870

PMID:41950518

Published:2026-04-08

research field:肿瘤学基因递送生物工程免疫学材料科学癌症免疫治疗纳米医学

Abstract

Chimeric antigen receptor-T (CAR-T) adoptive transfer therapy has shown remarkable efficacy in hematologic malignancies. However, the therapeutic efficacy of CAR-T in treating solid tumors, particularly “cold tumors” such as prostate cancer, is significantly restricted by the cumbersome ex vivo manufacturing, impaired T cell fitness, and an immunosuppressive tumor microenvironment that blunts T cell function. Here, we successfully constructed a nanodelivery system based on zeolitic imidazolate framework-8 (ZIF-8). This system exhibited high CAR-gene encapsulation efficiency, reduced nonspecific hepatic accumulation, targeted delivery to tumor-associated macrophages (TAMs), and efficient intracellular gene transfection efficiency, enabling in situ construction of chimeric antigen receptor macrophage (CAR-M). Co-delivery of IFN-γ and CAR genes not only maintained the specific tumor-killing and phagocytic activity of CAR-Ms against tumor cells but also activated adaptive immunity, inducing excellent antitumor efficacy, as evidenced by the observed 95.54% inhibition of tumor growth in a prostate cancer mouse model. This strategy provides a promising approach for systematic in vivo editing of CAR-Ms.

本文使用的Yeasen产品

购物车
客服
转染试用